Filtered By:
Drug: Fortamet

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 446 results found since Jan 2013.

Neuro-Protective Role of Metformin in Patients with Acute Stroke and Type 2 Diabetes Mellitus via AMPK/Mammalian Target of Rapamycin (mTOR) Signaling Pathway and Oxidative Stress.
CONCLUSIONS Metformin can improve the neurological function and oxidative stress status of acute stroke patients with type 2 diabetes, and its mechanism may be related to the AMPK/mTOR signaling pathway and oxidative stress. PMID: 30905926 [PubMed - in process]
Source: Medical Science Monitor - March 26, 2019 Category: Research Tags: Med Sci Monit Source Type: research

Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance
Conclusions Metformin and sitagliptin were both effective in reducing fasting glucose and HbA1c levels in patients with recent TIA or minor ischaemic stroke and IGT. However, the reduction of glucose levels and sample size was relatively small. The clinical relevance, therefore, needs to be tempered. A phase III trial is needed to investigate whether medical treatment, compared with lifestyle intervention or a combination of both, not only improves glucose metabolism in IGT, but also leads to reduction of recurrent TIA or ischaemic stroke in these patients. Trial registration number NL3048.
Source: BMJ Open - September 16, 2021 Category: General Medicine Authors: Osei, E., Zandbergen, A., Brouwers, P. J. A. M., Mulder, L. J. M. M., Koudstaal, P., Lingsma, H., Dippel, D. W. J., den Hertog, H. Tags: Open access, Neurology Source Type: research

The effect of chronic exposure to metformin in a new type-2 diabetic NONcNZO10/LtJ mouse model of stroke
CONCLUSION: The study suggests that the prolonged effect of metformin-induced euglycemia promoted the microglial activation, reduced neuronal cell death, and improved the overall survival following stroke, without any change in infarct size.PMID:35792967 | DOI:10.1007/s43440-022-00382-z
Source: Pharmacological Reports - July 6, 2022 Category: Drugs & Pharmacology Authors: Rashmi Kumari Lisa Willing Scot R Kimball Ian A Simpson Source Type: research

Metformin Treatment in the Period After Stroke Prevents Nitrative Stress and Restores Angiogenic Signaling in the Brain in Diabetes
Diabetes impedes vascular repair and causes vasoregression in the brain after stroke, but mechanisms underlying this response are still unclear. We hypothesized that excess peroxynitrite formation in diabetic ischemia/reperfusion (I/R) injury inactivates the p85 subunit of phosphoinositide 3-kinase (PI3K) by nitration and diverts the PI3K–Akt survival signal to the p38–mitogen-activated protein kinase apoptosis pathway. Nitrotyrosine (NY), Akt and p38 activity, p85 nitration, and caspase-3 cleavage were measured in brains from control, diabetic (GK), or metformin-treated GK rats subjected to sham or stroke surg...
Source: Diabetes - April 23, 2015 Category: Endocrinology Authors: Abdelsaid, M.; Prakash, R.; Li, W.; Coucha, M.; Hafez, S.; Johnson, M. H.; Fagan, S. C.; Ergul, A. Tags: Pharmacology and Therapeutics Source Type: research

Case–control study of second‐line therapies for type 2 diabetes in combination with metformin and the comparative risks of myocardial infarction and stroke
ABSTRACT We conducted a population‐based case–control study to assess the myocardial infarction (MI) and stroke risks associated with sulfonylureas and insulin when used in combination with metformin. Cases had type 2 diabetes and used metformin + insulin or metformin + sulfonylureas at the time of a first MI or first stroke from 1995–2010; controls used the same treatment combinations and were randomly sampled from the same population. MI and stroke diagnoses and potential confounders were validated by medical record reviews. Compared with metformin + sulfonylurea, metformin + insulin was associated ...
Source: Diabetes, Obesity and Metabolism - July 14, 2015 Category: Endocrinology Authors: James S. Floyd, Kerri L. Wiggins, Colleen M. Sitlani, James H. Flory, Sascha Dublin, Nicholas L. Smith, Susan R. Heckbert, Bruce M. Psaty Tags: Research Letter Source Type: research

Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial
Background: Impaired glucose tolerance is present in one third of patients with a TIA or ischemic stroke and is associated with a two-fold risk of recurrent stroke. Metformin improves glucose tolerance, but often leads to side effects.The aim of this study is to explore the feasibility, safety, and effects on glucose metabolism of metformin and sitagliptin in patients with TIA or minor ischemic stroke and impaired glucose tolerance. We will also assess whether a slow increase in metformin dose and better support and information on this treatment will reduce the incidence of side effects in these patients.Methods/DesignThe ...
Source: Trials - August 5, 2015 Category: Journals (General) Authors: Elizabeth OseiSusanne FonvilleAdrienne ZandbergenPaul BrouwersLaus MulderHester LingsmaDiederik DippelPeter KoudstaalHeleen den Hertog Source Type: research

Drug repurposing for immune modulation in acute ischemic stroke.
Abstract Innate immune cells play a dualistic role in the evolution of ischemic brain damage, with classic phenotypes promoting injury, and alternatively activated M2 microglia/macrophages or N2 neutrophils providing tissue remodelling and repair. Recently, a number of drugs commonly used for other indications (i.e., azithromycin, minocycline, bexarotene, rosiglitazone, metformin) was reported to provide neuroprotection in preclinical stroke models by promoting immune polarization towards non-inflammatory, protective phenotypes. Repurposing drugs with a well-established safety profile should allow a reduction in t...
Source: Current Opinion in Pharmacology - December 1, 2015 Category: Drugs & Pharmacology Authors: Amantea D, Bagetta G Tags: Curr Opin Pharmacol Source Type: research

Offsetting the impact of smoking and e-cigarette vaping on the cerebrovascular system and stroke injury: Is Metformin a viable countermeasure?
In this study we provide additional in vivo evidence showing that MF can effectively reduce the oxidative and inflammatory risk for stroke and attenuate post-ischemic brain injury promoted by TS and e-Cig vaping. Our data also suggest that MF administration could be extended as prophylactic care during the time window required for the renormalization of the risk levels of stroke following smoking cessation thus further studies in that direction are warrated. Graphical abstract
Source: Redox Biology - June 22, 2017 Category: Biology Source Type: research

Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study
ConclusionsSulphonylurea use was associated with higher risks of incident AF, stroke, cardiovascular mortality and all-cause mortality compared to metformin. Males and patients older than 65  years with sulphonylurea use were exposed to the highest risks.
Source: Acta Diabetologica - February 3, 2022 Category: Endocrinology Source Type: research

Stroke in the patient with diabetes (Part 2) -Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies
There is a higher incidence of stroke in both the type 2 diabetic and the non-diabetic insulin resistant patient which is accompanied by higher morbidity and mortality. Stroke primary prevention can be achieved by controlling atrial fibrillation and hypertension, and the utilization of statins and anticoagulant therapies. Utilizing pioglitazone and GLP-1 receptor agonists reduce the risk of stroke while the utilization of metformin, α-glucosidase inhibitors, DPP-4 and SGLT-2 inhibitors have no effect.
Source: Diabetes Research and Clinical Practice - May 11, 2020 Category: Endocrinology Authors: David S.H. Bell, Edison Goncalves Tags: Review Source Type: research

Ischemic stroke and reperfusion therapies in diabetic patients
ConclusionThe study shed light on diabetic patients and stroke RT highlighting the protective effect of metformin in IVT and the role of glycemia, weight, and combined treatment in MT.
Source: Neurological Sciences - February 11, 2022 Category: Neurology Source Type: research

Metformin enhances neural precursor cells migration and functional recovery after ischemic stroke in mice
Exp Brain Res. 2023 Jan 8. doi: 10.1007/s00221-023-06547-3. Online ahead of print.ABSTRACTResident neural precursor cells (NPCs) activation is a promising therapeutic strategy for brain repair. This strategy involves stimulating multiple stages of NPCs development, including proliferation, self-renewal, migration, and differentiation. Metformin, an FDA-approved diabetes drug, has been shown to promote the proliferation and differentiation of NPCs. However, it is still unclear whether metformin promotes the migration of NPCs. EVOS living cell imaging system was used for observing the migration for primary NPCs dynamically i...
Source: Brain Research - January 7, 2023 Category: Neurology Authors: Liang Zhang Jing Zhang Xiaoming Zhu Wei Jiao Yang Yang Youping Wu Likun Yang Yuhai Wang Source Type: research